Dr. Abbey Presents ARCHER II Clinical Trial Data at The Retina Society Annual Scientific Meeting
Texas Retina’s Ashkan Abbey, MD, presented baseline characteristics of participants in the Phase 3 ARCHER II clinical trial for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) at the 59th
read more
Dr. Abbey Discusses the New Era of Geographic Atrophy Management
Texas Retina’s Ashkan M. Abbey, MD, recently participated in a three-part special report video series by Ophthalmology Times that examined the evolving treatment landscape for geographic atrophy (GA). What is Geographic Atrophy?
read more Dr. Abbey Shares 36-Month Results of Pegcetacoplan Treatment for Geographic Atrophy in AMD
On behalf of the investigators for the OAKS, DERBY, and GALE clinical trials, Texas Retina’s Director of Clinical Research for Dallas, Ashkan Abbey, MD, co-authored an article titled, “Pegcetacoplan Treatment for Geographic
read more
Dr. Abbey Presents GALE Study Data at the Association for Research in Vision and Ophthalmology
At this year’s ARVO 2024, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), Texas Retina’s Dr. Abbey presented 36-month data from the GALE study of pegcetacoplan (brand
read more
New Clinical Trials Available at Texas Retina
At Texas Retina Associates, we remain committed to conducting ongoing research that will improve care for our patients, and over the past 20 years, our research program has grown to become one
read more
New Treatments Available for Geographic Atrophy
We know geographic atrophy (GA) can negatively impact patients’ quality of life and independence. While it still cannot be cured, Texas Retina is excited to finally have two new GA treatment options
read more Texas Retina Associates First in U.S. to Dose a Patient in the Phase 2 SIGLEC Trial
On June 1, 2023, Ashkan Abbey, MD, dosed the first patient in the Phase II SIGLEC Trial, a clinical study evaluating AVD-104, a potential new treatment for geographic atrophy (GA) from age-related
read more